Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TEAD1 | P28347 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738426 | 0.81 | SPHK1 (0.43) | SIRT1ALDH1A1SMN1; SMN2GAASIGMAR1 | |
| SCHEMBL1034082 | 0.81 | SPHK1 (0.43) | SIRT1ALDH1A1SMN1; SMN2GAASIGMAR1 | |
| SCHEMBL3173400 | 0.76 | SPHK1 (0.45) | SMN1; SMN2 | |
| SCHEMBL20791371 | 0.76 | ALDH1A1 (0.63) | SIRT2SIRT1KDM4EALDH1A1TEAD1 | |
| SCHEMBL28107119 | 0.76 | ALDH1A1 (0.63) | SIRT2SIRT1KDM4EALDH1A1TEAD1 | |
| SCHEMBL1031622 | 0.75 | GRM2 (0.48) | SIGMAR1 | |
| SCHEMBL28952343 | 0.75 | ALDH1A1 (0.69) | SIRT2SIRT1KDM4EALDH1A1TEAD1 | |
| SCHEMBL144107 | 0.74 | HRH3 (0.49) | KDM4ETEAD1GAATDP1 | |
| SCHEMBL15007429 | 0.73 | SPHK1 (0.46) | SIRT1 | |
| SCHEMBL3743415 | 0.72 | GRM2 (0.45) | KDM4EALDH1A1GAATDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869053-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| US-7829568-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-11-09 | — | — | US | claimed |
| EP-1869038-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-07-08 | — | — | EP | claimed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| US-7829568-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | SULT1E1, CYP4B1, CYP3A4 | SIRT2 77/4885SIRT1 240/4885KDM4E 67/4885 |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | P2RX5, P2RX4, P2RX7 | SIRT2 946/4885SIRT1 830/4885KDM4E 1123/4885 |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | CYP3A7, CYP3A5, CYP2D6 | SIRT2 509/4885SIRT1 583/4885KDM4E 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.